Psychopharmacology

While many deaths due to opioid overdoses are accidental, there a growing body of evidence that some cases were intentional and that the presence of pain played a role in the decision to end life.

Should hallucinogens such as ketamine, MDMA, psilocybin, and LSD be considered as treatment options for patients with mental illness?

Despite the proven efficacy and safety of medications for ADHD, abuse is a growing concern.

Seven common questions about addiction clinicians regularly hear-as well as the answers.

Recent findings suggest that the magnitude of efficacy for most antidepressants compared with placebo may be more modest than previously thought.

A novel compound holds promise for addressing cognitive deficits in schizophrenia.

An exploration of findings from contemporary research that hint at the unexplored hallucinogenic potential of ketamine and considerations for future investigation.

No better time than the summer to digest and reflect on the richness of our field and how we can implement advances in our own work.

A review of systemic medications for dermatologic diseases describes a wide range of adverse events, which range from mild and reversible to permanent and potentially fatal.

The impetus to consider inflammation as potentially relevant to the pathoetiology of domain-based psychopathology (eg, anhedonia) and/or mental disorders, is provided by a confluence of factors discussed here.

The studies reviewed in this article provide a new model for clinical practice-one where the treatment of depressed patients is not governed by trial and error, but rather where patients can access new interventions sooner.

A drug once seen as a widespread danger to society is now experiencing renewed interest as a treatment for medical conditions, including a number of mental health conditions. This brief review explores 5 key issues clinicians can consider when encountering the therapeutic cannabis user.

Make the most of brief psychotherapeutic sessions with these practical tips.

In the elderly, falls are a common and important problem. In the US, fall-related injuries cost approximately $30 billion per year, and about 30% of older adults fall at least once in a given year.

The name of the subspecialty Psychosomatic Medicine has become Consultation-Liaison Psychiatry. And the Academy of Psychosomatic Medicine has changed its name to the Academy of Consultation-Liaison Psychiatry. Here's why.

When patients endure repeated trials of medications to no avail in the areas of PTSD, panic disorder, bulimia nervosa, and other illnesses, psychiatrists are there.

Motivational interviewing can be very useful for addressing patients' ambivalence about psychopharmacologic issues. Take the quiz and learn more.

Here's a hit list of publications devoted to psychotherapy topics; to issues in genomic medicine; the impact of technology, and burnout on the practice of medicine; and to more traditional clinical articles addressing diagnosis and treatment of psychiatric disorders.

High treatment failure rates make it critical for prescribers to know how to safely and effectively switch antidepressants to ensure patient-treatment targets are met.

This year we asked about the best and worst things relating to our field. As always, we received a diverse group of responses.

This Special Report on treatment resistance provides expert guidance on how to treat patients who are still unresponsive after multiple unsuccessful attempts at intervention for some common mental disorders.

Trauma-focused cognitive-behavioral therapy, pharmacotherapy, and combinations thereof. Expert guidance here.

While treatment of bipolar disorder challenging , the notion that it is treatment resistant is contradicted by longitudinal and treatment research that indicates high rates of remission over time, moderate rates of recovery, and significant response to structured treatments tailored to symptoms.

This article focuses on treatment resistance to medications in adult male and non-pregnant adult female outpatients with any type of DSM-5 diagnosed bipolar disorder.

Recommendations from an international panel of experts on the management of MDD.

Treatment nonadherence in psychiatric patients contributes to increased suicide rates, illness exacerbation, hospitalization, and mortality. This Special Report countdown highlights the psychiatrist’s role in addressing barriers to treatment in a number of scenarios.

New evidence bolsters the reputation of clozapine as the “gold-standard” antipsychotic for patients with treatment-resistant schizophrenia.

The authors outline a series of strategies that can help promote adherence to the therapeutic regimen.

Is an effective, well-tolerated treatment for the negative symptoms of schizophrenia on the horizon?

This article delineates the role of psychiatrists in preventing HIV transmission before and after HIV exposure through pre- and post-exposure prophylaxis.